Jamal G. Misleh
Hematology | Oncology | Internal Medicine
651 North Broad Street
Suite 406
Middletown, DE 19709
Suite 406
Middletown, DE 19709
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions.
Journal: JCO precision oncology
Published: December 22, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
Journal: Blood advances
Published: December 02, 2024
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2023
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Journal: Haematologica
Published: July 10, 2023
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Journal: Cancer research communications
Published: January 17, 2023
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Journal: The Lancet. Haematology
Published: June 07, 2022
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Journal: Communications medicine
Published: January 25, 2022
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 14, 2021
Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.
Journal: Clinical epigenetics
Published: October 14, 2018
Longitudinal Relationship Between Frailty and Cognition in Patients 50 Years and Older with Breast Cancer.
Journal: Journal of the American Geriatrics Society
Published: August 16, 2018
Last Updated: 09/26/2026